MarketPeel
Insider Trading Intelligence
MO

Mike Ouimette

PLRX
GENERAL COUNSEL & CORP. SEC'Y · PLIANT THERAPEUTICS, INC. · CIK 0001822619
FILING MIX · LIFETIME52%/48%
BUYS
15
SELLS
14
TOTAL VALUE
$2.15M
COMPANIES
1
ACTIVE SINCE
Oct 2020
HOLDINGS NOW
105,544
AVG SELL PX
$20.05
TRADE KIND
SHOWING 29 / 29
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
12 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Mike Ouimette, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d12+83.33%+0.32%+0.45%-0.13%-2.82%
14d12+33.33%+4.02%+0.47%+3.54%+1.75%
30d12+58.33%-10.64%+0.24%-10.89%-0.88%
60d12+75.00%-11.26%+1.30%-12.56%-17.43%
90d12+66.67%-20.48%+1.11%-21.60%-25.33%
180d12+58.33%-24.88%+9.09%-33.97%-39.29%
1y12+100.00%-46.14%+23.44%-69.58%-68.96%
2y12(3 pending)+100.00%-76.35%+47.71%-124.06%-134.21%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PLRX · 105,544 shares · as of Jan 23, 2025
027,06054,12081,180108,24020212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
FLOW · 15 buys / 14 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,00070,000Jan 23, 2025Jan 27, 2025View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,000105,544Jan 23, 2025Jan 27, 2025View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,230$10.99$112.5K70,544Jan 22, 2025Jan 22, 2025View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,270$11.20$148.6K80,774Jan 17, 2025Jan 22, 2025View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,656$11.56$88.5K94,044Jul 10, 2024Jul 12, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,954101,700Jul 9, 2024Jul 11, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,50086,746Jan 23, 2024Jan 24, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
63,00063,000Jan 23, 2024Jan 24, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,197$17.23$89.5K55,246Jan 17, 2024Jan 19, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,755$17.55$83.5K60,443Jul 20, 2023Jul 21, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,778$18.01$230.1K65,198Jul 17, 2023Jul 19, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,18777,976Jul 14, 2023Jul 18, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
200$27.46$5.5K50,789Apr 3, 2023Apr 3, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,677$26.74$71.6K50,989Apr 3, 2023Apr 3, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,874$26.52$129.3K53,666Mar 30, 2023Apr 3, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,59358,540Mar 29, 2023Mar 31, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
39,00044,947Jan 25, 2023Jan 27, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,00055,000Jan 25, 2023Jan 27, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
General Counsel & Corp. Sec'y
10,00098,240Jan 23, 2023Jan 25, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
General Counsel & Corp. Sec'y
10,000$11.86$118.6K15,947Jan 23, 2023Jan 25, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
General Counsel & Corp. Sec'y
20,000$34.19$683.9K5,947Jan 23, 2023Jan 25, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
General Counsel & Corp. Sec'y
10,000$24.32$243.2K25,947Jan 23, 2023Jan 25, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
General Counsel & Corp. Sec'y
10,00077,000Jan 23, 2023Jan 25, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
General Counsel & Corp. Sec'y
2,928$19.38$56.7K5,947Dec 22, 2022Dec 23, 2022View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
General Counsel & Corp. Sec'y
4,719$19.10$90.1K8,875Dec 20, 2022Dec 21, 2022View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,59413,594Dec 19, 2022Dec 21, 2022View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
87,00087,000Jan 26, 2022Feb 2, 2022View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,52015,520Jan 23, 2021Jan 26, 2021View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
108,240108,240Oct 9, 2020Oct 13, 2020View →
Other insiders · PLRX
Loading peer insiders…
About this filer
CIK 0001822619
ROLE
General Counsel & Corp. Sec'y
PRIMARY
PLRX
COMPANIES
1
ACTIVE SINCE
Oct 2020
MARKETPEEL · /INSIDER/0001822619DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback